METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis.
The data from the METEOR trial show that asymptomatic low-risk patients treated with rosuvastatin have a reduction in progression of carotid intima-media thickness (CIMT) over 2 years versus placebo. ORIGINAL ARTICLE: Crouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
Haddad
Rudy M
RM
, , Erin Duchan MD 1 Neil D. Patel MD 1 Cynthia Feucht PharmD BCPS 1 1Michigan State University Kalamazoo Center for Medical Studies Kalamazoo MI 2Ferris State University College of Pharmacy Big Rapids MI Correspondence: Erin Duchan MD Michigan State University Kalamazoo Center for Medical Studies 1000 Oakland Dr. Kalamazoo MI 49008. Tel: 269-337-6450 E-mail: duchan@kcms.msu.edu, , .
Ballantyne
Christie M
CM
D050197:Atherosclerosis / Q000188:drug therapy*; D002339:Carotid Arteries / Q000187:drug effects*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D017539:Tunica Intima / Q000187:drug effects*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides